Compare CTRM & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRM | NEUP |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | Cyprus | United States |
| Employees | N/A | 8 |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 23.1M |
| IPO Year | 2017 | N/A |
| Metric | CTRM | NEUP |
|---|---|---|
| Price | $1.97 | $3.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 34.9K | ★ 206.9K |
| Earning Date | 04-15-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.66 | $3.19 |
| 52 Week High | $2.65 | $21.31 |
| Indicator | CTRM | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 53.40 |
| Support Level | $1.85 | $3.91 |
| Resistance Level | $2.15 | $4.31 |
| Average True Range (ATR) | 0.10 | 0.24 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 37.93 | 72.83 |
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments, namely (i) the dry bulk segment, (ii) the containership segment, and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.